Regeneron Pharmaceuticals
REGN
742.12
+3.40
+0.46%
Regeneron Pharmaceuticals
US · REGN
#285 by market cap
Listed 1970
742.12
+3.40
+0.46%
Live - 5344 symbols - heartbeat 386s ago
· 2026-10-08 07:44
Pre-market
742.12
0.00%
After-hours
742.12
0.00%
Overnight
741.93
-0.03%
- Market cap
- 76.40B
- P/E (TTM)i
- 18.36
- P/Bi
- 2.41
- EPSi
- 41.48
- Div yieldi
- 0.49%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on REGN?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 19 analysts
Buy
Avg price target
841.37 +13.4%
Price target rangecurrent 742.12
Low700.00
Avg841.37
High1,030.00
Buy 63%
Hold 37%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-25 | J.P. Morgan | -- | BUY | 900.00 |
| 2026-09-10 | HSBC | -- | BUY | 920.00 |
| 2026-08-17 | Leerink Partners | -- | HOLD | 824.00 |
| 2026-08-05 | Barclays | -- | BUY | 917.00 |
| 2026-08-04 | J.P. Morgan | -- | BUY | 900.00 |
| 2026-08-03 | Guggenheim | -- | BUY | 1,030.00 |
| 2026-07-31 | Wells Fargo | -- | HOLD | 750.00 |
| 2026-07-31 | Truist Financial | -- | BUY | 772.00 |
| 2026-07-31 | Baird | -- | HOLD | 761.00 |
| 2026-07-31 | Scotiabank | -- | HOLD | 770.00 |
| 2026-07-31 | Morgan Stanley | -- | HOLD | 758.00 |
| 2026-07-31 | BMO Capital | -- | BUY | 800.00 |
| 2026-07-31 | Barclays | -- | BUY | 917.00 |
| 2026-07-30 | TD Cowen | -- | BUY | 960.00 |
| 2026-07-30 | Cantor Fitzgerald | -- | BUY | 795.00 |
| 2026-07-30 | BofA Securities | -- | BUY | 891.00 |
| 2026-07-30 | Morgan Stanley | -- | HOLD | 758.00 |
| 2026-07-30 | Goldman Sachs | -- | BUY | 972.00 |
| 2026-07-30 | RBC Capital | -- | HOLD | 737.00 |
| 2026-07-22 | CCORF | -- | BUY | 875.00 |
| 2026-07-21 | Guggenheim | -- | BUY | 1,000.00 |
| 2026-07-20 | Goldman Sachs | -- | BUY | 965.00 |
| 2026-07-15 | Citi | -- | HOLD | 700.00 |
| 2026-07-13 | BofA Securities | -- | BUY | 856.00 |
| 2026-07-13 | BMO Capital | -- | BUY | 730.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
1 3
■ Upgrades■ Downgrades
- 1 upgrade vs 3 downgrades among tracked analyst rating changes.
- Most recent: Leerink Partners moved from Buy to Hold on 2026-08-17.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-17 | Leerink Partners | BUY → HOLD | 824.00 |
| 2026-05-17 | Citi | BUY → HOLD | 700.00 |
| 2026-01-07 | BofA Securities | SELL → BUY | 860.00 |
| 2025-12-03 | Morgan Stanley | BUY → HOLD | 767.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | -- | ±5.74% | +6.17% (beat) |
| 2026/Q1 | 2026-04-29 | -- | ±6.78% | -6.21% (in line) |
| 2025/Q4 | 2026-01-30 | -- | ±6.18% | -1.07% (in line) |
| 2025/Q3 | 2025-10-28 | -- | ±5.28% | +11.82% (beat) |
| 2025/Q2 | 2025-08-01 | -- | ±8.36% | +2.46% (in line) |
| 2025/Q1 | 2025-04-29 | -- | ±5.87% | -6.87% (beat) |
| 2024/Q4 | 2025-02-04 | -- | ±5.57% | +4.53% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±3.92% | -9.17% (beat) |
| 2024/Q2 | 2024-08-01 | -- | ±4.99% | +1.29% (in line) |
| 2024/Q1 | 2024-05-02 | -- | ±4.24% | +3.78% (in line) |
| 2023/Q4 | 2024-02-02 | -- | ±3.84% | -1.32% (in line) |
| 2023/Q3 | 2023-11-02 | -- | ±5.01% | +3.48% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:44:33 · For reference only, not investment advice and not tailored to your situation.